Document
IPR2023-00724, No. 1111 Exhibit - Exhibit 1111 Madsbad (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1111 Exhibit - Exhibit 1111 Madsbad (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2422 Exhibit - EX2422 Jentadueto® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2422 Exhibit - EX2422 Jentadueto® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2359 Exhibit - EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Diabetes Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medica...
Cite Document
IPR2023-00724, No. 2359 Exhibit - EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Diabetes Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medications, httpsw
+ More Snippets
Document
IPR2023-00724, No. 2453 Exhibit - EX2453 US Food Drug Administration, DrugsFDA, Synjardy (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2453 Exhibit - EX2453 US Food Drug Administration, DrugsFDA, Synjardy (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2479 Exhibit - EX2479 Nordrum, A, 11 Blockbuster Drugs to Watch in 2015, Intl Bus Times, httpwwwibtimescom11 blockbuster drugs watch 2015 1857100 Mar 24, 2015 (P....
Cite Document
IPR2023-00724, No. 2479 Exhibit - EX2479 Nordrum, A, 11 Blockbuster Drugs to Watch in 2015, Intl Bus Times, httpwwwibtimescom11 blockbuster drugs watch 2015 1857100 Mar 24, 2015 (P.T.A.B. Jan. 17, 2
+ More Snippets
Document
IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2545 Exhibit - EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 CFR 4222 and 42122b, Dr Reddy’s Laboratories Inc v Novo Nordisk AS, IPR2024 00009, P...
Cite Document
IPR2023-00724, No. 2545 Exhibit - EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 CFR 4222 and 42122b, Dr Reddy’s Laboratories Inc v Novo Nordisk AS, IPR2024 00009, Pap3 Oct 20, 2023
+ More Snippets
Document
IPR2023-00724, No. 2651 Exhibit - EX2651 Excerpt of Reply Expert Report of Dr Paul Dalby Regarding Inva lidity of US Patent No 10,335, 462, In re Ozempic Semaglutide Patent Litigation, No 1...
Cite Document
IPR2023-00724, No. 2651 Exhibit - EX2651 Excerpt of Reply Expert Report of Dr Paul Dalby Regarding Inva lidity of US Patent No 10,335, 462, In re Ozempic Semaglutide Patent Litigation, No 122 cv 030
+ More Snippets
Document
IPR2023-00724, No. 1001 Exhibit - US10335462 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1001 Exhibit - US10335462 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1017 Exhibit - US5512549 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1017 Exhibit - US5512549 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1069 Exhibit - Remington 20th ed (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1069 Exhibit - Remington 20th ed (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1049 Exhibit - ICH 1994 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1049 Exhibit - ICH 1994 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1082 Exhibit - Scheduling order (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1082 Exhibit - Scheduling order (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1012 Exhibit - Lovshin 2009 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1012 Exhibit - Lovshin 2009 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1014 Exhibit - NCT773 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1014 Exhibit - NCT773 (P.T.A.B. Mar. 16, 2023)
+ More Snippets